Abdulrahman Katib: Factor XI Inhibitors as the Next Frontier in the Thrombosis Treatment Landscape
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
“Factor XI inhibitors are quickly becoming one of the most intensely studied drug classes in thrombosis medicine today.
What makes them so exciting is the possibility of achieving meaningful antithrombotic protection while preserving hemostasis — something we have been striving for in anticoagulation for decades.
That said, true clinical efficacy still needs to be firmly established in some of our highest-risk populations, particularly cancer-associated thrombosis (CAT), where thrombosis biology and bleeding risk coexist in a very delicate balance.
On a personal level, I was truly privileged to be part of the MAGNOLIA and ASTER trials.
Being involved in research at this stage — before results are known — is a unique experience. It reminds you that every future guideline, every future practice change, starts with patients, investigators, and teams working together to answer difficult clinical questions.
I am genuinely looking forward to seeing the final publications and understanding where Factor XI inhibition will ultimately position itself in our thrombosis treatment landscape.”
More posts about Abdulrahman Katib.
-
Mar 17, 2026, 18:11Ossama Mansour: Landmark MENA Guidelines for Acute Ischemic Stroke Management
-
Mar 17, 2026, 17:48Andrea Van Beek: Improving DOAC Adherence Saves Lives
-
Mar 17, 2026, 17:43Soumen Bhattacharyya: Microangiopathic Hemolytic Anemia Is Often a Hematologic Clue to Underlying Malignancy
-
Mar 17, 2026, 17:37Peter Bou Dib: New Insights on Factor VIII and the Musculoskeletal System
-
Mar 17, 2026, 17:31Armghan Ans: The 2026 Stroke Guidelines Are Excellent, Now the Hard Part
-
Mar 17, 2026, 17:26Danny Hsu: Navigating a Rebalanced Hemostatic State in Decompensated Cirrhosis
-
Mar 17, 2026, 17:21Matías J Alet on Acute Ischemic Stroke With Low NIHSS at NeuroQuality
-
Mar 17, 2026, 17:16S1PR4 Controls Platelet Fibrinogen Binding and Thrombus Formation – JTH
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs